Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc.（NRIX）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · NRIX · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
29
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Nurix Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
NRIX 季度内部人买卖趋势
NRIX 内幕交易卖出 · NRIX 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · NRIX CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
NRIX 高管卖出股份 · NRIX 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 2, 2026 | Ring Christine Chief Legal Officer | Option | 3,422 | $6K | Form 4 |
| Jun 2, 2026 | Ring Christine Chief Legal Officer | Sale | 8,148 | $135K | Form 4 |
| May 5, 2026 | van Houte Hans CFO | Sale | 13,473 | $223K | Form 4 |
| May 5, 2026 | van Houte Hans CFO | Sale | 582 | $10K | Form 4 |
| May 4, 2026 | Ring Christine Chief Legal Officer | Sale | 8,148 | $138K | Form 4 |
| May 1, 2026 | Ring Christine Chief Legal Officer | Sale | 5,394 | $90K | Form 4 |
| Apr 30, 2026 | van Houte Hans CFO | Option | 2,858 | — | Form 4 |
| Apr 30, 2026 | van Houte Hans CFO | Sale | 2,388 | $40K | Form 4 |
| Apr 30, 2026 | van Houte Hans CFO | Option | 3,750 | — | Form 4 |
| Apr 30, 2026 | van Houte Hans CFO | Option | 2,000 | — | Form 4 |
| Apr 30, 2026 | Ring Christine Chief Legal Officer | Option | 2,858 | — | Form 4 |
| Apr 30, 2026 | Ring Christine Chief Legal Officer | Option | 3,750 | — | Form 4 |
| Apr 30, 2026 | Ring Christine Chief Legal Officer | Sale | 3,214 | $53K | Form 4 |
| Apr 30, 2026 | Ring Christine Chief Legal Officer | Option | 2,000 | — | Form 4 |
| Apr 30, 2026 | Hansen Gwenn Chief Scientific Officer | Option | 2,858 | — | Form 4 |
| Apr 30, 2026 | Hansen Gwenn Chief Scientific Officer | Option | 3,750 | — | Form 4 |
| Apr 30, 2026 | Hansen Gwenn Chief Scientific Officer | Sale | 3,214 | $53K | Form 4 |
| Apr 30, 2026 | Hansen Gwenn Chief Scientific Officer | Option | 2,000 | — | Form 4 |
| Apr 2, 2026 | Ring Christine Chief Legal Officer | Sale | 8,148 | $124K | Form 4 |
| Mar 2, 2026 | Ring Christine Chief Legal Officer | Sale | 8,148 | $126K | Form 4 |
| Feb 9, 2026 | Ring Christine Chief Legal Officer | Sale | 14,261 | $238K | Form 4 |
| Feb 3, 2026 | Hansen Gwenn Chief Scientific Officer | Option | 31,333 | $26K | Form 4 |
| Jan 30, 2026 | van Houte Hans CFO | Option | 2,859 | — | Form 4 |
| Jan 30, 2026 | van Houte Hans CFO | Option | 3,750 | — | Form 4 |
| Jan 30, 2026 | van Houte Hans CFO | Sale | 3,588 | $59K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 NRIX 内幕交易
NRIX 内幕交易
Nurix Therapeutics, Inc.（NRIX）内幕交易数据来源于公司内部人（包括Ring Christine (Chief Legal Officer), van Houte Hans (CFO), Hansen Gwenn (Chief Scientific Officer)）提交的SEC Form 4申报文件。过去12个月内，3位内部人向SEC提交了交易申报。NRIX内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Nurix Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
NRIX 内幕交易 · 5个问题Nurix Therapeutics, Inc.（NRIX）的内部人包括高管和董事，如Ring Christine (Chief Legal Officer), van Houte Hans (CFO), Hansen Gwenn (Chief Scientific Officer)等。过去12个月内，3位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026